Using a probiotic component to heal the gut and slow memory loss in aging and Alzheimer's
Microbial therapy improves gut permeability to reduce cognitive decline and Alzheimer’s disease
['FUNDING_R01'] · UNIVERSITY OF SOUTH FLORIDA · NIH-11146480
This project will test whether a heat-killed probiotic and its key cell-wall molecule can repair the gut's mucus barrier to reduce leakiness, inflammation, and memory loss linked to aging and Alzheimer's disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF SOUTH FLORIDA (nih funded) |
| Locations | 1 site (TAMPA, UNITED STATES) |
| Trial ID | NIH-11146480 on ClinicalTrials.gov |
What this research studies
From the patient's viewpoint, researchers are studying a human-derived probiotic strain (LpD3-5) and one of its molecules (LTA) that appear to boost the gut's mucus layer and reduce gut leakiness. Most experiments use aging and Alzheimer-model mice and lab tests to see if increasing mucus and goblet cells lowers gut and brain inflammation and improves memory. The team will study how LTA activates immune receptors (TLR2) to increase mucin production and whether this reduces hallmarks of Alzheimer's in the brain. The work aims to lay groundwork for treatments that could someday be tested in people with age-related memory loss or early Alzheimer's.
Who could benefit from this research
Good fit: Ideal candidates for future trials would be older adults with early memory problems or mild Alzheimer's disease who are otherwise medically stable.
Not a fit: People with advanced Alzheimer's, severe immune compromise, or memory loss from non-neurodegenerative causes are less likely to benefit from this approach.
Why it matters
Potential benefit: If successful, this could lead to a safe, microbiome-based way to slow memory decline and reduce Alzheimer’s-related brain changes by strengthening the gut barrier.
How similar studies have performed: Related probiotic and gut-targeting studies have shown promising benefits in animal models and limited human pilot work, but the specific heat-killed strain and LTA mechanism are novel and not yet proven in people.
Where this research is happening
TAMPA, UNITED STATES
- UNIVERSITY OF SOUTH FLORIDA — TAMPA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: YADAV, HARIOM — UNIVERSITY OF SOUTH FLORIDA
- Study coordinator: YADAV, HARIOM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.